2Shiozawa K, Watanabe M, Sumino Y. Evaluation of the hemodynamic status of focal hepatic lesions 20 mm or less in diameter by contrast-enhanced ultrasonography using Sonazoid. Intervirology. 2009;52:213-222. [PubMed] [DOI].
3Watanabe M, Shiozawa K, Takahashi M, Wakui N, Otsuka Y, Kaneko H, Tanikawa K, Shibuya K, Kamiyama N, Sumino Y. Parametric imaging using contrast-enhanced ultrasound with Sonazoid for hepatocellular carcinoma. J Med Ultrasonics. 2010;37:81-86. [DOI].
4Wakui N, Takayama R, Kanekawa T, Ichimori M, Otsuka T, Shinohara M, Ishii K, Kamiyama N, Sumino Y. Usefulness of arrival time parametric imaging in evaluating the degree of liver disease progression in chronic hepatitis C infection. J Ultrasound Med. 2012;31:373-382. [PubMed].
5Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, R?cken C, Malfertheiner P, Farrell GC. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006;43:134-143. [PubMed] [DOI].
6Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006;242:151-167. [PubMed] [DOI].
7Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des. 2007;13:3279-3287. [PubMed] [DOI].
8Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. [PubMed] [DOI].
9Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574. [PubMed] [DOI].
10Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des. 2002;8:2249-2253. [PubMed] [DOI].
